M. Mazza, G. Marano, G. Giuseppin
Apr 10, 2020
Citations
0
Influential Citations
0
Citations
Journal
Bipolar disorders
Abstract
Oral ziprasidone (ziprasidone hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA) in 2001 for the treatment of schizophrenia, and acute manic or mixed episodes associated with bipolar disorder (BPD) with or without psychotic features. Ziprasidone intramuscular (ziprasidone mesylate) is FDA-approved for acute agitation in patients with schizophrenia.